Last reviewed · How we verify
LNP-nCOV saRNA-02 Vaccine
LNP-nCOV saRNA-02 Vaccine is a Small molecule drug developed by MRC/UVRI and LSHTM Uganda Research Unit. It is currently in Phase 1 development.
At a glance
| Generic name | LNP-nCOV saRNA-02 Vaccine |
|---|---|
| Sponsor | MRC/UVRI and LSHTM Uganda Research Unit |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LNP-nCOV saRNA-02 Vaccine CI brief — competitive landscape report
- LNP-nCOV saRNA-02 Vaccine updates RSS · CI watch RSS
- MRC/UVRI and LSHTM Uganda Research Unit portfolio CI
Frequently asked questions about LNP-nCOV saRNA-02 Vaccine
What is LNP-nCOV saRNA-02 Vaccine?
LNP-nCOV saRNA-02 Vaccine is a Small molecule drug developed by MRC/UVRI and LSHTM Uganda Research Unit.
Who makes LNP-nCOV saRNA-02 Vaccine?
LNP-nCOV saRNA-02 Vaccine is developed by MRC/UVRI and LSHTM Uganda Research Unit (see full MRC/UVRI and LSHTM Uganda Research Unit pipeline at /company/mrc-uvri-and-lshtm-uganda-research-unit).
What development phase is LNP-nCOV saRNA-02 Vaccine in?
LNP-nCOV saRNA-02 Vaccine is in Phase 1.